###begin article-title 0
Postnatal Expansion of the Pancreatic beta-Cell Mass Is Dependent on Survivin
###end article-title 0
###begin p 1
###xml 40 63 40 63 <email xmlns:xlink="http://www.w3.org/1999/xlink">rachel_altura@brown.edu</email>
Corresponding author: Rachel A. Altura, rachel_altura@brown.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 381 389 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
OBJECTIVE-Diabetes results from a deficiency of functional beta-cells due to both an increase in beta-cell death and an inhibition of beta-cell replication. The molecular mechanisms responsible for these effects in susceptible individuals are mostly unknown. The objective of this study was to determine whether a gene critical for cell division and cell survival in cancer cells, survivin, might also be important for beta-cells.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 82 90 82 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax-6-</italic>
###xml 374 382 374 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
RESEARCH DESIGN AND METHODS-We generated mice harboring a conditional deletion of survivin in pancreatic endocrine cells using mice with a Pax-6-Cre transgene promoter construct driving tissue-specific expression of Cre-recombinase in these cells. We performed metabolic studies and immunohistochemical analyses to determine the effects of a mono- and biallelic deletion of survivin.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 30 38 30 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
RESULTS-Selective deletion of survivin in pancreatic endocrine cells in the mouse had no discernible effects during embryogenesis but was associated with striking decreases in beta-cell number after birth, leading to hyperglycemia and early-onset diabetes by 4 weeks of age. Serum insulin levels were significantly decreased in animals lacking endocrine cell survivin, with relative stability of other hormones. Exogenous expression of survivin in mature beta-cells lacking endogenous survivin completely rescued the hyperglycemic phenotype and the decrease in beta-cell mass, confirming the specificity of the survivin effect in these cells.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-Our findings implicate survivin in the maintenance of beta-cell mass through both replication and antiapoptotic mechanisms. Given the widespread involvement of survivin in cancer, a novel role for survivin may well be exploited in beta-cell regulation in diseased states, such as diabetes.
###end p 6
###begin p 7
Published ahead of print at  on 3 July 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 327 328 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 329 330 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 674 675 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 676 677 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 923 924 899 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 925 926 901 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 927 928 903 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 985 986 958 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 987 988 960 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1097 1098 1064 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1099 1101 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 484 489 <span type="species:ncbi:10090">mouse</span>
Production and maintenance of the pancreatic beta-cell mass is a highly regulated process driven by mechanisms that differ in developing compared with adult animals. These mechanisms include, but are not limited to, beta-cell replication, beta-cell hypertrophy, beta-cell differentiation (neogenesis), and beta-cell apoptosis (1-3), each having variable importance depending on the age of the animal and changes in the metabolic demands of the body. During early embryogenesis in the mouse, most beta-cells are generated through endocrine cell differentiation, a process that depends on key transcription factors, including Pdx1, Isl1, Nkx2.2, Nkx6.1, and the Maf proteins (4,5). Differentiated beta-cells first appear around embryonic day (E) 13 at the start of a wave of the secondary transition. During late embryogenesis (E18.5) and immediately after birth, a transient burst of replication of these beta-cells occurs (1,6,7) with a consequent marked increase in beta-cell growth (2,8). New beta-cells continue to form in the adult animal, primarily from the replication of mature beta-cells (9,10). The mechanism by which fully differentiated, mature beta-cells can reenter the cell cycle without undergoing a process of programmed cell death is unclear.
###end p 9
###begin p 10
###xml 87 95 84 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 256 258 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 259 261 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 368 370 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 477 479 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 674 676 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 727 729 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 759 761 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 906 914 903 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 987 989 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 1175 1177 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 1343 1345 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 1521 1523 1518 1520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 1575 1577 1572 1574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 1578 1580 1575 1577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 1615 1617 1612 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
An attractive candidate regulator of beta-cell replication and survival after birth is survivin, a cancer gene implicated in both the control of cell division and the regulation of apoptosis in cancer cells but with unknown functions in most normal cells (11-13). Survivin was originally discovered as a homolog to the inhibitor of apoptosis proteins in cancer cells (14). These proteins block the function of caspase proteins in the mitochondria-dependent cell death pathway (15), protecting cells from succumbing to a cascade of cellular and molecular events that characterize apoptosis. Survivin is a potent inhibitor of cell death in diverse malignant tumor cell types (11) and in some normal cells, including hepatocytes (16) and bone marrow stem cells (17). In addition, survivin also plays a role in cell division in some normal cells during embryogenesis and in cancer cells. Biallelic deletion of survivin in embryonic stem cells leads to embryonic lethality between E4 and E6 (18), with cells lacking survivin having abnormal, enlarged nuclei. This phenotype parallels that of other genetic models targeting proteins known as chromosomal passenger proteins (CPPs) (19). Survivin forms a complex with other CPPs and plays an active role in recruiting aurora kinase B to the kinetochore to ensure the proper regulation of cytokinesis (20). A clear understanding of how survivin regulates both cell division and apoptosis is not known. Some evidence suggests that the protein exists in multiple subcellular pools (21) and can interact with different partner proteins (22-24), including its own splice forms (25), to perform these different functions.
###end p 10
###begin p 11
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 605 607 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
Survivin is expressed in a range of normal embryonic tissues and in a restricted number of highly proliferative adult tissues (26), including bone marrow-derived stem cells (17) and neural progenitor cells (27). Its expression during both normal development and cancer suggests that it is a critical molecule for maintaining cellular homeostasis and that its aberrant regulation can contribute to either disease initiation or progression. Recently, exogenous expression of survivin in a streptozotocin-induced model of diabetes demonstrated protection of pancreatic beta-cells from programmed cell death (28). This provides some evidence that it may play a role as an apoptotic inhibitor in beta-cells in the setting of diabetes. Based on the bifunctional role of survivin in cancer and in stem cells, we hypothesized that it may play a role in the replication and/or survival of mature pancreatic beta-cells after birth.
###end p 11
###begin title 12
RESEARCH DESIGN AND METHODS
###end title 12
###begin p 13
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Le-Cre</italic>
###xml 69 75 69 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">tm1sor</sup>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 158 166 158 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP</italic>
###xml 199 207 199 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 207 214 207 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 207 214 207 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 264 272 264 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 284 292 284 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 316 324 316 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 324 331 324 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 324 331 324 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 349 357 349 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 358 366 358 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 366 373 366 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 366 373 366 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 443 451 443 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 530 538 530 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 538 545 538 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 538 545 538 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 583 591 583 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 592 599 592 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RIP-SVV</italic>
###xml 599 600 599 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 602 610 602 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 610 617 610 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 610 617 610 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 651 659 651 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 661 668 661 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RIP-SVV</italic>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 670 678 670 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 678 685 678 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 678 685 678 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 112 116 <span type="species:ncbi:10090">Mice</span>
###xml 152 157 <span type="species:ncbi:10090">mouse</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 293 297 <span type="species:ncbi:10090">mice</span>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
###xml 437 442 <span type="species:ncbi:10090">mouse</span>
###xml 482 485 <span type="species:ncbi:10116">rat</span>
###xml 546 550 <span type="species:ncbi:10090">mice</span>
###xml 596 599 <span type="species:ncbi:35246?0.41732283464566927">SVV</span>
###xml 665 668 <span type="species:ncbi:35246?0.41732283464566927">SVV</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
Pax6-Cre mice (also called Le-Cre) were crossed with B6;129S-Gtrosa26tm1sor mice to evaluate Cre activity (29). Mice harboring a conditionally targeted mouse survivin gene flanked by two loxP sites (survivinlox/lox) have been described previously (16,27), as have Pax6-Cre mice (30). Pax6-Cre mice were crossed with survivinlox/lox mice to generate Pax6-Cre;survivinlox/lox mice. For the rescue experiment, two lines of mice harboring a mouse survivin transgene under control of an rat insulin promoter (RIP) (28) were mated with survivinlox/lox mice. Offspring with the genotype of Pax6-Cre;RIP-SVV+; survivinlox/lox were compared with those of with Pax6-Cre; RIP-SVV-;survivinlox/lox mice. All experimental procedures were performed with the approval of the Institutional Animal Care and Use Committee. Islet isolation was as previously described (31).
###end p 13
###begin title 14
Morphometry and islet mass.
###end title 14
###begin p 15
Serial pancreatic sections were collected every 100 mum and stained with hematoxylin-eosin (H-E). Images were taken with a Leica microscope equipped with a SPOT RT KE digital camera (Diagnostic Instruments). Islet cell areas for the control and survivin knockout were measured by point counting morphometry (see the supplemental methods available in an online appendix at ).
###end p 15
###begin title 16
Immunohistochemistry.
###end title 16
###begin p 17
###xml 935 937 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 351 357 <span type="species:ncbi:9986">rabbit</span>
###xml 398 403 <span type="species:ncbi:10090">mouse</span>
###xml 447 453 <span type="species:ncbi:9986">rabbit</span>
###xml 526 532 <span type="species:ncbi:9986">rabbit</span>
###xml 557 567 <span type="species:ncbi:10141">guinea pig</span>
###xml 590 596 <span type="species:ncbi:9986">rabbit</span>
###xml 635 640 <span type="species:ncbi:10090">mouse</span>
###xml 688 693 <span type="species:ncbi:10090">mouse</span>
###xml 702 708 <span type="species:ncbi:9986">rabbit</span>
###xml 750 756 <span type="species:ncbi:9986">rabbit</span>
###xml 789 794 <span type="species:ncbi:10090">mouse</span>
###xml 830 835 <span type="species:ncbi:10090">mouse</span>
###xml 883 889 <span type="species:ncbi:9986">Rabbit</span>
Pancreata were fixed in either 10% neutral-buffered formalin or Histochoice (Ameresco), dehydrated through a graded series of ethanol, and embedded in paraffin wax. Sections were cut and stained with H-E. For fluorescent immunostaining, fresh frozen sections were cut and fixed in 4% paraformaldehyde. The primary antibodies used were survivin (TIAP; rabbit polyclonal, 1:200; Chemicon), glucagon (mouse monoclonal, 1:1,000; Sigma), somatostatin (rabbit polyclonal anti-srif28 IHC 8004, 1:1,000; Peninsula), active caspase 3 (rabbit, 1:20; Abcam), insulin (guinea pig, 1:200; Linco), MafB (rabbit, 1:100; Bethyl Laboratories), Nkx2.2 (mouse, 1:100; Developmental Studies Hybridoma Bank), mouse Nkx6.1 (rabbit, 1:500; provided by Dr. P. Serup), Pax6 (rabbit, 1:500; Covance), beta-catenin (mouse, 1:100; BD Biosciences), and Isl1 (mouse, 1:100; Developmental Studies Hybridoma Bank). Rabbit anti-MafA antibody was described previously (32). Apoptosis was assayed with the FragELTM kit (Calbiochem), according to the manufacturer's instructions.
###end p 17
###begin title 18
Metabolic studies.
###end title 18
###begin p 19
###xml 136 140 <span type="species:ncbi:10090">mice</span>
Serum blood glucoses were measured with One Touch InDuo Glucometer and test strips (Lifescan, Milpitas, CA). For the glucose challenge, mice were fasted then injected intraperitoneally with dextrose at 2 g/kg body wt. Blood glucose levels were subsequently measured at indicated times. Insulin challenge was performed in the fed state. A dose of 0.75 unit/kg body wt was injected intraperitoneally. Blood glucose levels were measured every 15 min for 90 min after injection. A minimum of four animals per group per time point was used for each of these measurements.
###end p 19
###begin title 20
RESULTS
###end title 20
###begin title 21
Survivin is dispensable for endocrine cell differentiation during embryogenesis.
###end title 21
###begin p 22
###xml 449 450 443 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 443 450 437 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 519 520 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 604 605 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 598 605 592 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 643 644 637 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 785 786 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 779 786 773 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 983 984 977 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 977 984 971 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 986 993 980 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel 2</italic>
###xml 1294 1296 1282 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1457 1465 1445 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1467 1474 1455 1462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insulin</italic>
###xml 1480 1520 1468 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glyceraldehyde-3-phosphate dehydrogenase</italic>
###xml 1542 1543 1530 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1770 1771 1755 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 1772 1774 1757 1759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 128 133 <span type="species:ncbi:10090">mouse</span>
###xml 1397 1401 <span type="species:ncbi:10090">mice</span>
To gain insight into the regulatory potential of survivin in pancreatic beta-cells, we determined its expression pattern in the mouse pancreas during normal embryonic development and after birth. Survivin protein was readily detected throughout the pancreatic epithelium, including endocrine cells during the secondary transition (E15.5), as shown by the cytoplasmic staining of survivin in cells that express beta-catenin, insulin, and Isl1 (Fig. 1A). Survivin expression gradually became restricted to endocrine (Isl1+) cells in late embryogenesis (E19.5) and postnatally (postnatal day [P] 14) (Fig. 1A). By P21, one can detect several Isl1+ cells that do not express survivin, suggesting a further restriction of survivin expression to a subpopulation(s) of endocrine cells (Fig. 1A). Colocalization of survivin with insulin was also observed at these time points, with a relative lack of survivin staining within cells that stained positive for glucagon and somatostatin (Fig. 1A, panel 2), suggesting that survivin expression becomes restricted to beta-cells by P21. Expression of survivin in mature, differentiated beta-cells after birth was unexpected, because activation of this gene was previously reported only in undifferentiated and highly proliferating cells in the adult animal (26). Therefore, we confirmed the expression of survivin in these cells by isolating islets from normal mice at 1 and 2 weeks after birth and performing RT-PCR for survivin, insulin, and glyceraldehyde-3-phosphate dehydrogenase (supplementary Fig. 1A. The pattern of survivin expression within the pancreas is similar to the reported pattern of key transcription factors that contribute to beta-cell development during embryogenesis and after birth, including Nkx6.1 and Pdx1 (5,33). It is possible that such factors may restrict survivin expression to beta-cells during the postnatal period.
###end p 22
###begin p 23
###xml 131 139 131 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Le-Cre</italic>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6</italic>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 649 653 649 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6</italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6</italic>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 948 956 948 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 1020 1022 1020 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gt</italic>
###xml 1023 1027 1023 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ROSA</italic>
###xml 1028 1033 1028 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">26Sor</italic>
###xml 1033 1039 1033 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink">tm1Sor</sup>
###xml 1234 1238 1231 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6</italic>
###xml 1301 1302 1298 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 343 348 <span type="species:ncbi:10090">mouse</span>
###xml 643 648 <span type="species:ncbi:10090">mouse</span>
###xml 957 961 <span type="species:ncbi:10090">mice</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
To examine the functional role of survivin in all pancreatic endocrine cells both during embryogenesis and after birth, we chose a Pax6-Cre transgene construct (also known as Le-Cre) that drives tissue-specific expression of Cre-recombinase in the cells expressing Pax6 (30). The onset of endogenous Pax6 expression normally occurs at E9.5 in mouse endocrine progenitors and persists in mature endocrine cells throughout development and postnatally, thus providing us with a tool to examine the role of survivin in all endocrine cells during fetal development and postnatally (30,34). The construct incorporated a 6.5-kb genomic region of the mouse Pax6 promoter that has been previously shown to initiate transcription of Pax6 in the lens and in developing pancreatic endocrine cells but not in other pancreatic cells or in the central nervous system (34). We further characterized the expression pattern of Cre-recombinase within the pancreas of Pax6-Cre mice after birth by mating them with Rosa26 Cre-reporter mice [Gt(ROSA)26Sortm1Sor], collecting pancreatic tissues, and staining sections with X-Gal. beta-Galactosidase was expressed in all endocrine-producing cells but not in exocrine cells, confirming the specificity of the Pax6 promoter within the pancreas after birth (supplementary Fig. 1B).
###end p 23
###begin p 24
###xml 148 156 148 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 199 207 199 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP</italic>
###xml 251 259 251 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 260 268 260 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 268 275 268 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 268 275 268 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 291 299 291 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 338 346 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 517 518 517 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 511 518 511 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 520 527 520 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel 1</italic>
###xml 582 590 582 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 647 648 647 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 769 770 757 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1004 1012 980 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1056 1064 1032 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 1065 1073 1041 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1073 1080 1049 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 1073 1080 1049 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 1138 1146 1114 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1249 1250 1225 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1273 1281 1249 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 193 198 <span type="species:ncbi:10090">mouse</span>
###xml 276 280 <span type="species:ncbi:10090">mice</span>
###xml 397 401 <span type="species:ncbi:10090">mice</span>
To determine the potential effects of survivin on endocrine cell differentiation during embryogenesis and its effects on cell survival after birth, Pax6-Cre mice were bred to mice carrying the mouse survivin gene flanked by two loxP sites, generating Pax6-Cre;survivinlox/lox mice, deleting survivin in Pax6-expressing cells. Deletion of survivin within the pancreatic endocrine cells of affected mice was confirmed both by staining pancreas tissue from control and mutant animals with an antibody to survivin (Fig. 1B, panel 1) and by performing PCR for the deleted and nondeleted survivin alleles on isolated islet cell DNA (supplementary Fig. 1C). Quantification of survivin and insulin protein in the knockout animals showed that only approximately6% of all insulin+ cells expressed survivin. By comparison, all insulin-expressing cells in control animals expressed survivin; therefore, we estimated a approximately94% efficiency of recombination in this model. To demonstrate the specificity of the survivin deletion to pancreatic endocrine tissue of Pax6-Cre;survivinlox/lox animals, we performed PCR for the deleted and nondeleted survivin alleles in tissues outside the pancreas, including liver, muscle, fat, and brain (supplementary Fig. 1D), and showed that the survivin gene was largely intact in these other tissues. A minor amount of a second product was detected in fat that may represent the deleted allele. This could indicate that there is some recombination in fat; however, no prior evidence of Pax6 expression in adipose tissue has been reported.
###end p 24
###begin p 25
###xml 321 322 321 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 315 322 315 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 324 332 324 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panels 2</italic>
###xml 337 338 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 643 651 643 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 743 751 743 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 895 903 895 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 904 912 904 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 912 919 912 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 912 919 912 919 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 920 924 <span type="species:ncbi:10090">mice</span>
Examination of the expression pattern of key proteins in endocrine cell differentiation during embryogenesis showed that mice lacking endocrine-survivin had essentially the same expression pattern of these factors (Pdx1, Isl1, Nkx2.2, and the Maf proteins) in endocrine precursors as did their littermate controls (Fig. 1B, panels 2 and 3). Based on these data, survivin may be dispensable for the proliferation of pancreatic progenitors and the differentiation of pancreatic endocrine cells during embryogenesis. The lack of identifiable effects on cell number during this time period was somewhat surprising because conventional deletion of survivin in embryonic stem cells resulted in early embryonic lethality (18) and because deletion of survivin at E9.5 in neural stem cells led to significant embryonic neural stem cell loss and death immediately after birth (27). By contrast, here, all Pax6-Cre;survivinlox/lox mice were born in the expected Mendelian ratios, suggesting no embryonic lethality, and had birth weights and sizes similar to those of littermate controls (not shown), suggesting no significant metabolic effects in utero.
###end p 25
###begin title 26
Survivin is required for mature beta-cell function after birth.
###end title 26
###begin p 27
###xml 180 188 180 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 189 197 189 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 197 204 197 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 197 204 197 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 250 258 250 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 362 370 362 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 378 385 378 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 421 429 421 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 430 438 430 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 438 445 438 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 438 445 438 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 482 483 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 476 483 476 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 590 591 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 584 591 584 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 729 730 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 723 730 723 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 752 760 752 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 761 769 761 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 769 776 769 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 769 776 769 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 908 909 908 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 902 909 902 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 1245 1246 1245 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1239 1246 1239 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 1377 1385 1377 1385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1387 1395 1387 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 1396 1404 1396 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1404 1407 1404 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 1404 1409 1404 1409 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox</italic>/+</sup>
###xml 1535 1536 1535 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1737 1738 1737 1738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
###xml 676 680 <span type="species:ncbi:10090">mice</span>
###xml 777 781 <span type="species:ncbi:10090">mice</span>
###xml 1103 1107 <span type="species:ncbi:10090">mice</span>
###xml 1138 1142 <span type="species:ncbi:10090">mice</span>
###xml 1336 1340 <span type="species:ncbi:10090">Mice</span>
###xml 1410 1414 <span type="species:ncbi:10090">mice</span>
To determine the potential physiological effects of survivin loss within the endocrine cells after birth, we performed serial metabolic studies on mice lacking endocrine-survivin (Pax6-Cre;survivinlox/lox mice). During the first 3 weeks after birth, survivin-deficient animals had random glucose levels that were similar to their littermate controls with intact survivin genes (Fig. 2A). At 4 weeks of life, however, the Pax6-Cre;survivinlox/lox mice developed hyperglycemia (Fig. 2A) and a reduced glucose tolerance, as determined by injection with 2 g/kg dextrose after a 5-h fast (Fig. 2B), findings consistent with early-onset diabetes. The glucose abnormalities in these mice became more striking as the animals aged (Fig. 2A). At 4 weeks of age, Pax6-Cre;survivinlox/lox mice responded similarly to littermate control animals when treated with the same doses (0.75 unit/kg) of exogenous insulin (Fig. 2C), consistent with a primary lack of insulin availability as the cause of the hyperglycemia due to a loss of survivin. To further understand this process, we quantified the serum insulin of the mice over time. Survivin-deficient mice had very low to undetectable (below assay threshold) insulin levels from 3 to 13 weeks of life (Fig. 2D; supplementary Table 1), suggesting either a failure of insulin production or secretion. Mice with a one-allele loss of endocrine-survivin (Pax6-Cre;survivinlox/+ mice) had 12-h fasting glucose levels that were comparable with control animals at 4 and 5 weeks of age (supplementary Fig. 2A). At 17 weeks of age, however, these heterozygotes began to develop some signs of glucose intolerance, as shown by their higher serum glucose levels after dextrose administration (supplementary Fig. 2B).
###end p 27
###begin p 28
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 9 17 9 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 17 24 17 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 253 260 253 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">urvivin</italic>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 539 540 539 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 711 712 711 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 320 325 <span type="species:ncbi:9606">human</span>
###xml 749 754 <span type="species:ncbi:9606">human</span>
###xml 771 775 <span type="species:ncbi:10090">mice</span>
Pax6-Cre;survivinlox/lox mice that remained untreated and therefore exposed to high serum glucose levels for several months after birth became relatively resistant to exogenous insulin, as would be expected (supplementary Fig. 3A). Many of these older survivin-deficient mice also developed other metabolic hallmarks of human diabetes, including metabolic acidosis, hyperkalemia, polyuria, and ketonuria (supplementary Fig. 3B; supplementary Table 2). In addition, they developed hypertriglyceridemia, hypoproteinemia (supplementary Fig. 3C; supplementary Table 2), and pathological evidence of fatty livers, most likely due to the secondary effects of prolonged glucose and lipid toxicity (supplementary Fig. 3D), findings reminiscent of untreated human diabetes. These mice ultimately showed poor weight gain and signs of dehydration and had shortened life spans of 4-7 months.
###end p 28
###begin p 29
###xml 230 238 230 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 430 431 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 424 431 424 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 458 459 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 452 459 452 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 731 732 720 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 725 732 714 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 780 781 769 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 774 781 763 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
To determine the cause of the metabolic abnormalities resulting from the low serum insulin levels, we examined pancreatic sections from the mice for pathological abnormalities over time. The onset of hyperglycemia in mice lacking survivin within endocrine cells was associated with a significant decrease in the number of insulin-producing cells after 4 weeks of age as measured by immunohistochemical staining for insulin (Fig. 3A) and by islet mass (Fig. 4A), suggesting that there was a lack of insulin production due to an inappropriate decrease in beta-cell number. By contrast, a decrease in the number or function of alpha- and delta-cells, as determined by immunohistochemical staining for glucagon and somatostatin (Fig. 3A) and by measuring serum glucagon levels (Fig. 3B), was not observed during the early postnatal period. The findings of hyperglycemia, insulin deficiency, and a lack of insulin-producing beta-cells in the face of a relative preservation of alpha- and delta-cells suggest that survivin plays an essential role in the regulation of beta-cell number early after birth, preferentially affecting these cells over other endocrine subtypes. Given the known mechanisms of survivin function in cancer cells, both as an inhibitor of apoptosis and a regulator of cell division, survivin could have either one or both functions in pancreatic beta-cells.
###end p 29
###begin title 30
Survivin regulates beta-cell mass after birth.
###end title 30
###begin p 31
###xml 29 37 29 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 161 169 155 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 170 178 164 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 178 185 172 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 178 185 172 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 229 237 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 415 423 406 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 485 486 476 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 493 494 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 510 511 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 504 511 495 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 581 582 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 589 590 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 606 607 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 600 607 591 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 746 754 737 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 945 946 935 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 976 977 965 966 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 990 991 979 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 998 999 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1015 1016 1004 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1021 1022 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1009 1022 998 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic> and <italic>C</italic></xref>
###xml 1128 1130 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 1131 1133 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 1168 1176 1157 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1231 1233 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 1180 1186 <span type="species:ncbi:10090">murine</span>
To establish the effect of a survivin deletion on the onset and extent of beta-cell expansion, we compared the total mass of beta-cells as a function of time in Pax6-Cre;survivinlox/lox versus littermate controls containing both survivin alleles. Although the beta-cell masses of the control and mutant animals were similar at birth, beginning at 2 weeks of age they became significantly smaller in animals lacking survivin within these cells (0.17 vs. 0.41 mg in littermate controls [n = 5], P < 0.001; Fig. 4A), reaching a 10-fold reduction at 8 weeks of life (0.12 vs. 1.29 mg [n = 4], P < 0.001; Fig. 4A). Serial examination of pancreatic tissue collected from control and mutant animals at P0 and at 1, 2, and 3 weeks of age showed that the survivin-deficient cells had many enlarged, dysmorphic nuclei, characterized by an increase in nuclear size that was not apparent in the littermate control cells (mean nuclear size, 37.3 vs. 30.9 mum2 at 2 weeks; 39.7 vs. 31.5 mum2 at 3 weeks [n = 5], P < 0.001; Fig. 4B and C). This phenotype is similar to that described after the disruption of survivin in cultured cancer cells (35,36) and after homozygous deletion of survivin in murine embryonic cells during early embryogenesis (18). The morphological defects observed in the beta-cells lacking survivin are consistent with defective cell division, suggesting that survivin may play a role in beta-cell replication.
###end p 31
###begin title 32
Survivin regulates cell division and protects cells against cell death.
###end title 32
###begin p 33
###xml 446 454 443 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 483 484 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 477 484 471 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 534 535 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 833 841 827 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 865 866 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 859 866 853 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 1129 1137 1123 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1173 1174 1167 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1167 1174 1161 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 1199 1207 1193 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1257 1258 1251 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1251 1258 1245 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 1631 1634 1622 1625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p21</italic>
###xml 1634 1638 1625 1629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1</italic>
###xml 1634 1638 1625 1629 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1</italic></sup>
###xml 1679 1687 1670 1678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin E</italic>
###xml 1695 1703 1686 1694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1727 1728 1718 1719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1721 1728 1712 1719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 1782 1790 1773 1781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin A</italic>
###xml 1792 1794 1783 1785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B1</italic>
###xml 1796 1798 1787 1789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2</italic>
###xml 1800 1801 1791 1792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1803 1805 1794 1796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D1</italic>
###xml 1807 1808 1798 1799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1810 1813 1801 1804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p27</italic>
###xml 1815 1819 1806 1810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdk2</italic>
###xml 1824 1828 1815 1819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdk4</italic>
###xml 1846 1847 1837 1838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1840 1847 1831 1838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 2032 2036 2020 2024 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WAF1</sup>
###xml 2122 2124 2110 2112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 2125 2127 2113 2115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
To test the hypothesis that survivin regulates cell division and/or cell death in pancreatic beta-cells during a time period shortly after birth, we examined tissue sections isolated from 2-week-old animals for the expression of proliferating cell nuclear antigen (PCNA), a marker of cell cycle proliferation, and for transferase-mediated dUTP nick-end labeling (TUNEL), a marker for apoptosis. We observed a 50% decrease in PCNA staining in the survivin-deficient beta-cells (Fig. 5A) but no significant change in the number of TUNEL+ cells (not shown). To increase the sensitivity for the detection of cell death, we isolated islet cells from the pancreata of 1- to 2-week-old animals and subjected them to functional caspase 3 activity assays. With this methodology, we did observe a twofold increase in caspase 3 activity in the survivin-deficient cells (Fig. 5B), suggesting an effect on a caspase 3-dependent cell death pathway. To further characterize the cell cycle abnormalities, we performed flow cytometry analyses on the same isolated islets. This revealed an excess of cells with >4N modal chromosome numbers in the survivin-deficient islets (14 vs. 9%; Fig. 5C) and an accumulation of survivin-deficient islets in late S/G2 (36 vs. 23%; Fig. 5C), suggesting a delay in cell cycle progression. To attempt to gain further insight into potential cell cycle proteins regulated by survivin in beta-cells, we performed quantitative PCR on RNA from the isolated islets for genes involved in cell cycle progression. These analyses revealed a significant (average threefold) increase in expression of the cell cycle inhibitor p21WAF1 and a twofold decrease in expression in cyclin E in the survivin-deficient cells (Fig. 5D). No significant changes in the expression levels of Cyclin A, B1, B2, C, D1, F, p27, Cdk2, or Cdk4 were seen (Fig. 5D). Taken together, our findings support the hypothesis that survivin regulates cell cycle progression in pancreatic beta-cells. These effects could be mediated through repression of p21WAF1, which might occur as a consequence of survivin-dependent repression of p53 protein (37,38).
###end p 33
###begin title 34
Survivin is functionally specific for mature pancreatic beta-cells.
###end title 34
###begin p 35
###xml 122 130 119 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 131 139 128 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 139 146 136 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 139 146 136 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 240 249 237 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax-6-Cre</italic>
###xml 250 258 247 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 258 265 255 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 258 265 255 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 266 273 263 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RIP-SVV</italic>
###xml 415 424 412 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax-6-Cre</italic>
###xml 425 433 422 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 433 440 430 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 433 440 430 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 441 448 438 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RIP-SVV</italic>
###xml 508 515 505 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RIP-SVV</italic>
###xml 517 526 514 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax-6-Cre</italic>
###xml 527 535 524 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 535 542 532 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 535 542 532 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 548 556 545 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 556 563 553 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 556 563 553 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 576 577 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 570 577 567 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 674 682 671 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 683 691 680 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 691 698 688 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 691 698 688 695 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 743 744 740 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 737 744 734 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 786 787 783 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 780 787 777 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 157 172 <span type="species:ncbi:10090">transgenic mice</span>
###xml 270 273 <span type="species:ncbi:35246?0.41732283464566927">SVV</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 309 324 <span type="species:ncbi:10090">transgenic mice</span>
###xml 445 448 <span type="species:ncbi:35246?0.41732283464566927">SVV</span>
###xml 449 453 <span type="species:ncbi:10090">mice</span>
###xml 512 515 <span type="species:ncbi:35246?0.41732283464566927">SVV</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
To establish survivin as a specific regulator of beta-cell mass distinct from other endocrine cell subtypes, we mated the Pax6-Cre;survivinlox/lox mice with transgenic mice expressing the survivin protein under control of the RIP (yielding Pax-6-Cre;survivinlox/lox;RIP-SVV mice). We then followed the triple transgenic mice from birth to 8 weeks of age, measuring weekly random serum glucose concentrations in the Pax-6-Cre;survivinlox/lox;RIP-SVV mice and comparing these with random glucose levels in the RIP-SVV, Pax-6-Cre;survivinlox/lox, and survivinlox/lox mice (Fig. 6A). RIP-driven transgenic expression of survivin completely rescued the diabetic phenotype of the Pax6-Cre;survivinlox/lox mice. It also restored normal growth (Fig. 6B, 12 weeks) and mass of the islets (Fig. 6C). This finding supports a major role for survivin in maintaining beta-cell number and function in normal animals after birth.
###end p 35
###begin title 36
DISCUSSION
###end title 36
###begin p 37
###xml 342 350 336 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 798 806 789 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1644 1652 1632 1640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1748 1756 1733 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1582 1587 <span type="species:ncbi:10090">mouse</span>
In this work, we show that survivin, a protein involved in both replication and apoptosis in cancer cells, plays an important role in the maintenance of mature pancreatic beta-cells after birth. Toward the end of embryonic development, survivin expression becomes restricted to beta-cells within the endocrine pancreas. Genetic disruption of survivin in all pancreatic endocrine cell types results in a selective decrease in the pancreatic beta-cell mass early after birth, beginning at 2 weeks of life. Animals lacking survivin within their pancreatic endocrine cells become hyperglycemic and are unable to produce sufficient amounts of insulin by 4 weeks of life but maintain production of other endocrine hormones, including glucagon and somatostatin. Interestingly, blood glucose levels in the survivin-deficient animals were not significantly increased at 3 weeks of age, although insulin levels were at least twofold below normal. A likely explanation for the relative normoglycemia at 3 weeks of life is that the animals were maintained on a low-carbohydrate (maternal milk) diet, and, thus, the requirements for insulin were low. Once the animals were weaned to a high-carbohydrate (standard chow) diet between 3 and 4 weeks, however, the requirement for insulin increased, resulting in significant hyperglycemia in the absence of endogenous insulin. Because of the hepatic and renal toxicity resulting from massive hyperglycemia over time, the animals lacking survivin had shortened life spans. This dramatic phenotype was completely reversed by exogenously expressing the mouse survivin protein in mature pancreatic beta-cells of the survivin-deficient animals. The molecular mechanism underlying the loss of pancreatic beta-cells in the survivin-deficient animals, although limited because of the in vivo nature of this study, is supportive of a defect in both cell cycle progression and an apoptotic pathway.
###end p 37
###begin p 38
###xml 55 56 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 148 149 145 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 744 746 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 1067 1069 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 1070 1072 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 1347 1349 1332 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 1350 1352 1335 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 613 618 <span type="species:ncbi:9606">human</span>
###xml 898 903 <span type="species:ncbi:10090">mouse</span>
Some intriguing questions generated from this work are 1) why does survivin more selectively affect beta-cells over other endocrine cell types, and 2) why are there no observable effects of a loss of survivin during embryogenesis? One answer to the cell-selective effect may be that the expression levels of survivin in the beta-cells are much higher than those in the other endocrine subtypes and that a critical level of survivin is necessary to confer its function. This hypothesis is consistent with the data here and also with the effects observed in cancer cells; high levels of survivin found in malignant human tumor cells promote tumor cell survival, whereas low survivin levels inherent to benign tumors confer no survival advantage (13). Prior evidence for a requirement for beta-cell-specific cell cycle proteins, like survivin, for precise regulation of proliferation comes from whole mouse knockout models of other proteins, such as CDK4, that give rise to a selective beta-cell phenotype, without affecting additional endocrine or exocrine cell types (39,40). With regard to the timing of survivin loss during early embryogenesis and its effect on postnatal beta-cells, this could be due to a specific necessity for its activation during the rapid proliferative phase between the end of embryogenesis and the first 2 weeks of life (41,42). To answer these questions more definitively, signaling pathways that control the regulation of survivin protein during embryogenesis and after birth will need to be explored.
###end p 38
###begin p 39
###xml 29 30 29 30 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 338 346 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 528 536 528 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 635 639 635 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdk4</italic>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 661 665 661 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdk4</italic>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 1102 1106 1102 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdk4</italic>
###xml 1207 1209 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 1331 1333 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 1582 1586 1576 1580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdk4</italic>
###xml 1591 1599 1585 1593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1650 1658 1644 1652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1956 1960 1947 1951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdk4</italic>
###xml 359 364 <span type="species:ncbi:10090">mouse</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
###xml 843 847 <span type="species:ncbi:10090">mice</span>
###xml 885 889 <span type="species:ncbi:10090">mice</span>
###xml 1112 1116 <span type="species:ncbi:10090">mice</span>
###xml 1966 1971 <span type="species:ncbi:10090">mouse</span>
In the mammalian cell cycle, d-type cyclins bind to and activate the cyclin-dependent kinase protein CDK4 during G1, and, together, they coordinate the transition from G1 to S phase via phosphorylation of Rb protein and release of the transcriptional activator E2F1 (43-45). Previously, we have shown that E2F1 binds to and activates the survivin promoter in mouse embryonic fibroblasts and is responsible, in part, for its cell-cycle dependency (46). The spontaneous development of insulin-deficient diabetes after deletion of survivin within the endocrine pancreas is strikingly similar to the phenotype observed after disruption of Cdk4 in ES cells (39,40). Cdk4-null mice develop diabetes manifested by hyperglycemia, polyuria, and low serum insulin levels within the first 2 months of life (39,40). Sections of pancreas tissue from these mice, like those from the survivin mutant mice, show a decrease in islet cell mass with a selective decrease in the expression of insulin and a relative preservation of glucagon, somatostatin, and pancreatic polypeptide. In addition, pancreas tissue from the Cdk4-null mice show evidence of both a decrease in beta-cell proliferation and an increase in apoptosis (40), the latter likely induced after activation of a cell cycle checkpoint in response to a lack of cell cycle progression (47). Thus, survivin is much like CDK4 in that it can selectively regulate beta-cell growth during the postnatal period and, when inactivated, causes a slowing of cell cycle progression and an increase in apoptosis. Given the similar phenotypes of the Cdk4 and survivin knockout animals, the E2F1-mediated regulation of survivin transcription, and the activation of E2F1 by the CDK4/CyclinD complex, survivin fits well within the molecular pathway of these proteins and likely functions to assist them in modulating beta-cell replication after birth. Further work showing that transgenic expression of survivin can rescue the Cdk4-null mouse diabetic phenotype, currently underway, would confirm this hypothesis.
###end p 39
###begin p 40
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 425 428 425 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p21</italic>
###xml 428 432 428 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1</italic>
###xml 428 432 428 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1</italic></sup>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r51">51</xref>
###xml 786 788 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r52">52</xref>
###xml 810 812 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r53">53</xref>
###xml 904 906 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r53">53</xref>
###xml 1059 1061 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
###xml 711 716 <span type="species:ncbi:9606">human</span>
###xml 721 726 <span type="species:ncbi:10090">mouse</span>
Although limited by the in vivo nature of this study, by the technical difficulty of isolating sufficient numbers of islet cells from young (1- to 2-week-old) survivin mutant mice for protein analysis, and by the extremely low in vitro replication rates of primary islet cells (0.06-0.15% per day) (48), by isolating some islets from the mutant mice, we were able to use quantitative PCR to identify the cell cycle regulator p21WAF1 as consistently induced in islet cells that lacked survivin. p21 protein, within a family of proteins that also includes p27 and p57, can function to inhibit (49-51) cyclin-dependent kinases, leading to a decrease in the rate of cell cycle progression. p21 is expressed in both human and mouse beta-cells and is induced in response to beta-cell injury (52) and growth factors (53). Functionally, islet cells lacking p21 grow faster than those with an intact p21 protein (53). Interestingly, p21 is not induced by metabolic signals, leading to a suggestion that it specifically acts to inhibit mitogenic signals in beta-cells (54). If p21 is a true downstream target of survivin in beta-cells, then upregulation of survivin during the developmental period of beta-cell growth may result in a decrease in p21 activity, releasing the cells to proceed through the cell cycle.
###end p 40
###begin p 41
###xml 215 216 212 213 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 371 372 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 373 375 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 376 378 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r55">55</xref>
###xml 738 740 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r56">56</xref>
Although dispensable for the differentiation of endocrine cells during embryonic development, survivin fits well within the framework of known mediators of cell cycle progression in mature beta-cells, including the d-type cyclins, the cyclin-dependent kinases, the E2F/RB family of proteins, and the moderators of these molecules, the cyclin-dependent kinase inhibitors (9,54,55). Our data strongly support a critical role for survivin in the maintenance of the beta-cell mass in the early postnatal period. Understanding beta-cell mass regulation is critical to understanding the pathogenesis of diabetes and to islet cell transplantation protocols. Our findings suggest that current efforts to regenerate and expand the beta-cell mass (56) will need to consider the novel role of survivin during this process.
###end p 41
###begin title 42
Supplementary Material
###end title 42
###begin title 43
Online-Only Appendix
###end title 43
###begin p 44
W.N. is a recipient of the Mary K. Iacocca Fellowship. D.C.A. has received National Institutes of Health grants CA-78810, CA-90917, and HL-54131. A.S. has received National Institutes of Health Grant DK-060127. R.A.A. has received support from the Juvenile Diabetes Research Foundation and National Institutes of Health Grant 1R21-DK-078300-01.
###end p 44
###begin p 45
###xml 212 220 212 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 220 227 220 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 220 227 220 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 280 286 280 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Le-Cre</italic>
###xml 108 116 <span type="species:ncbi:9606">Children</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
We are grateful for the technical assistance of Florinda Jaynes, Vera Small, and Cindy McAllister (Columbus Children's Hospital) and of Varisha Parikh (Joslin Diabetes Institute) and for the generous gift of the survivinlox/lox mice from the laboratory of Dr. E.M. Conway and the Le-Cre mice from the laboratory of Dr. Ruth Ashery-Paden. We also thank Dr. Susan Bonner-Weir for her helpful discussions, protocols, and general enthusiasm. We thank John Gilbert for his thoughtful comments on this manuscript.
###end p 45
###begin title 46
REFERENCES
###end title 46
###begin p 47
###xml 76 77 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 438 439 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 445 446 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 502 503 493 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 613 614 601 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 657 658 644 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 747 755 734 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-cre</italic>
###xml 756 764 743 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 764 771 751 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 764 771 751 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 772 776 <span type="species:ncbi:10090">mice</span>
Survivin expression becomes gradually restricted to beta-cells after birth. A: Survivin expression in pancreatic endocrine and exocrine cells from E15.5 to P21, assessed by immunofluorescent staining of pancreatic tissue isolated from wild-type mice, using antibodies to survivin, beta-catenin, Isl1, insulin (Ins), glucagon (Gluc), and somatostatin (Som). Survivin is expressed throughout the pancreatic epithelium at E15.5 (beta-catenin+, Isl1+ cells), becomes gradually restricted to endocrine (Isl1+) cells in late embryogenesis (E19.5) and postnatally (P14), and then is further restricted to beta-cells (Ins+) by P21. Magnification x20. Bar = 20 mum. B: Analysis of expression of differentiation markers in pancreatic sections isolated from Pax6-cre;survivinlox/lox mice and their littermate controls. Comparisons between mutant (MUT) and littermate controls (WT) indicated similar patterns and levels of expression at E15.5 and E19.5. Magnification x20. Bar = 20 mum. (Please see  for a high-quality digital representation of this image.)
###end p 47
###begin p 48
###xml 56 57 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 117 125 115 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 125 128 123 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 125 130 123 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox</italic>/+</sup>
###xml 134 142 132 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 142 149 140 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 142 149 140 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 160 161 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 201 209 199 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 221 229 219 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 230 238 228 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 238 245 236 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 238 245 236 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 282 283 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 354 355 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 364 365 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 448 449 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 470 478 440 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 519 520 463 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 632 633 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 642 643 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 721 722 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 743 751 687 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 792 793 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 928 929 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1101 1102 1019 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1147 1155 1052 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax-6Cre</italic>
###xml 1156 1164 1061 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1164 1171 1069 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 1164 1171 1069 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 1181 1182 1086 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 526 530 <span type="species:ncbi:10090">mice</span>
###xml 799 803 <span type="species:ncbi:10090">mice</span>
Loss of survivin results in insulin-deficient diabetes. A: Mean (+/-SD) random glucose levels in littermate control (survivinlox/+ or survivinlox/lox) mice (o, n = 8 at each time point) and homozygous survivin-deficient (Pax6-Cre;survivinlox/lox) mice (blacksquare, square, filled, n = 8 at each time point) at various ages after birth. *Significance at P < 0.01. B: Glucose tolerance test (mean +/- SD) in 6-week-old male littermates. Control (o, n = 7) and homozygous survivin-deficient (blacksquare, square, filled, n = 7) mice were fasted for 5 h then injected with dextrose (2 g/kg body wt) intraperitoneally. *Significance at P < 0.05. C: Insulin challenge test in 4-week-old littermates. Four-week-old control (o, n = 3) and homozygous survivin-deficient (blacksquare, square, filled, n = 4) mice were injected with 0.75 unit/kg insulin (fed state). No statistically significant differences were found at any time point. D: Random serum insulin levels measured by enzyme-linked immunosorbent assay in age-matched animals at the indicated times. o, insulin levels in individual control animals (n = 16); black triangle, levels in individual Pax-6Cre;survivinlox/lox animals (n = 12). See supplementary Table 1 for individual values.
###end p 48
###begin p 49
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 231 239 231 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax-6Cre</italic>
###xml 240 248 240 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 248 255 248 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 248 255 248 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 284 285 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 436 437 407 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 453 462 419 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax-6-Cre</italic>
###xml 463 471 429 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 471 478 437 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 471 478 437 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 485 486 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 222 226 <span type="species:ncbi:10090">mice</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
Loss of insulin-producing cells in survivin-deficient animals. A: Insulin, glucagon, and somatostatin expression in 3- and 12-week-old animals, shown by immunochemical staining of pancreatic sections isolated from control mice and Pax-6Cre;survivinlox/lox littermates. Bars = 40 mum. B: Mean (+/-SD) serum glucagon levels measured by immunoassay in age-matched animals at the indicated times. blacksquare, square, filled, control mice (n = 21); square, Pax-6-Cre;survivinlox/lox mice (n = 25). (Please see  for a high-quality digital representation of this image.)
###end p 49
###begin p 50
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 286 287 258 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 340 348 312 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 368 369 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 477 478 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 500 501 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 750 751 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 784 785 744 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 832 833 766 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 848 856 777 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 875 876 804 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 900 901 829 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Loss of islet cell mass and nuclear abnormalities in survivin-deficient mice. A: Expansion of the endocrine cell mass after birth. Pancreatic tissue was isolated from age-matched animals at the indicated times. The mean (+/- SD) islet cell mass of control (blacksquare, square, filled, n = 8 [P0], 3 [P7], 5 [P14], 4 [P21], and 4 [8W]) and survivin-deficient (square, n = 7 [P0], 3 [P7], 5 [P14], 4 [P21], and 4 [8W]) tissues was calculated by point morphometry. *Significant (P < 0.001) difference. B: beta-Cell size differences in affected animals. Pancreatic tissue isolated from animals at the indicated times was stained with H-E and visualized by light microscopy. Mutant beta-cells with enlarged nuclei are indicated by arrows. Bars = 20 mum. C: Nuclear size measurements from B. blacksquare, square, filled, control tissue (n = 5); square, survivin-deficient tissue (n = 5). *Significance at P < 0.001. (Please see  for a high-quality digital representation of this image.)
###end p 50
###begin p 51
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 161 169 161 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 197 198 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 274 275 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 352 353 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 362 363 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 532 540 499 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 709 710 643 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 719 720 653 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 824 832 758 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-cre</italic>
###xml 833 841 767 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 841 848 775 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 841 848 775 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 979 987 913 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1036 1037 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1196 1204 1104 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-cre</italic>
###xml 1205 1213 1113 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 1213 1220 1121 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 1213 1220 1121 1128 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
Defects in replication and apoptosis pathways. A: PCNA staining of pancreatic tissues indicates a 50% decrease in the proliferation of islet cells isolated from survivin-deficient animals (square, n = 5) compared with their littermate controls (blacksquare, square, filled, n = 5). Data are mean (+/-SD) percentages of positive cells. *Significance at P < 0.05. B: Caspase 3 activity assays performed on islets isolated from 2-week-old mice indicate a two- to threefold increase in caspase 3 activation in islet cells isolated from survivin-deficient animals (square) compared with their littermate controls (blacksquare, square, filled). Data are mean (+/-SD) percentages of positive cells. *Significance at P < 0.05. C: Aberrant cell cycle progression in islet cells lacking survivin. Islet cells isolated from 2-week-old Pax6-cre;survivinlox/lox mice and their littermate controls were fixed, stained with propidium iodide, and analyzed by flow cytometry. Comparisons between survivin-deficient animals and their controls are shown. D: Fold changes in the expression of the indicated genes as determined by quantitative PCR of isolated islets at 1-2 weeks of age. blacksquare, square, filled, Pax6-cre;survivinlox/lox cells in comparison with controls. Data are mean (+/-SD).
###end p 51
###begin p 52
###xml 94 102 94 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 103 111 103 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 111 118 111 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 111 118 111 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 125 126 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 167 175 165 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 176 184 174 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 184 191 182 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 184 191 182 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 193 194 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 219 227 217 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 228 236 226 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 236 243 234 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 236 243 234 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 244 251 242 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RIP-SVV</italic>
###xml 253 254 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 261 268 259 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RIP-SVV</italic>
###xml 270 271 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 282 290 280 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 290 297 288 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 290 297 288 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 313 314 311 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 368 369 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 378 379 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 433 434 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 469 470 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 491 498 488 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RIP-SVV</italic>
###xml 529 530 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 540 548 511 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pax6-Cre</italic>
###xml 549 556 520 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RIP-SVV</italic>
###xml 557 565 528 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 565 572 536 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</italic>
###xml 565 572 536 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lox/lox</italic></sup>
###xml 582 583 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 248 251 <span type="species:ncbi:35246?0.41732283464566927">SVV</span>
###xml 265 268 <span type="species:ncbi:35246?0.41732283464566927">SVV</span>
###xml 307 311 <span type="species:ncbi:10090">mice</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 495 498 <span type="species:ncbi:35246?0.41732283464566927">SVV</span>
###xml 553 556 <span type="species:ncbi:35246?0.41732283464566927">SVV</span>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
Survivin, under control of the RIP, rescues the diabetic phenotype and islet cell mass of the Pax6-Cre;survivinlox/lox mice. A: Mean (+/- SD) random glucose levels in Pax6-Cre;survivinlox/lox (n = 7) mice compared with Pax6-Cre;survivinlox/lox;RIP-SVV (n = 6), RIP-SVV (n = 5), and survivinlox/lox (SVVl/l) mice (n = 6) from 4 to 8 weeks after birth. *Significance at P < 0.05. B: Representative islet cell morphology of the mice in A at 12 weeks of age. Bar = 40 mum. C: Islet cell mass in RIP-SVV (blacksquare, square, filled, n = 4) and Pax6-Cre;RIP-SVV;survivinlox/lox (square, n = 4) mice. No statistically significant differences were found. (Please see  for a high-quality digital representation of this image.)
###end p 52

